Gabriele SME, Martin MJ, Kesselheim AS - National Institutes of Health (NIH)
The commenters support finalizing NIH’s proposed policy requiring licensees of NIH-developed technologies to submit access plans, recommending the inclusion of reasonable pricing commitments in such access planning. They also urge the agency to require public disclosure of access plans, consider patent type and license exclusivity when evaluating plans, and implement systematic annual reporting to monitor licensee compliance.
VIEW SOURCE
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine
Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open